Trial finds combination of pancreatic cancer drugs extends survival

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology
February 2, 2017
Rheumatoid arthritis update: Cardiovascular disease, rheumatoid arthritis vs. lupus, psoriatic arthritis
February 2, 2017
Show all

Trial finds combination of pancreatic cancer drugs extends survival

Researchers are considering it a ‘monumental leap forward’ for treating pancreatic cancer.

Cancer campaigners are hailing a “monumental leap forward” in pancreatic cancer treatment after a new drug trial significantly extended survival from what is the most lethal form of the disease.

The clinical trial found that 29% of patients given a combination of two chemotherapy drugs lived for at least five years compared with 16% who received the one chemotherapy drug that is still the NHS’s standard treatment.

The results are important because they could lead to an improvement in the prospects for people who develop pancreatic cancer, which has the lowest survival rates among the 21 most common forms of the disease and kills 8,800 Britons a year. Only one in 100 people survive for 10 or more years after their diagnosis.

“These results are a monumental leap forward in pancreatic cancer treatment. We believe this could herald a true step change in the treatment of this tough cancer, offering substantially more patients who have had surgery the chance to live for longer and, crucially, without significant added side-effects,” said Leanne Reynolds, head of research at the charity Pancreatic Cancer UK.

Read full article: Trial finds combination of pancreatic cancer drugs extends survival | Science | The Guardian

Read Full Article: Trial finds combination of pancreatic cancer drugs extends survival | Science | The Guardian

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.